Research ArticleFibrosis

Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis

See allHide authors and affiliations

Science Translational Medicine  30 Oct 2019:
Vol. 11, Issue 516, eaau6296
DOI: 10.1126/scitranslmed.aau6296

A rewarding treatment for fibrosis

Recent data have shown that Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) play an important role in fibroblast activation during fibrosis. Now, Haak et al. developed a therapeutic approach for inhibiting YAP/TAZ specifically in fibroblasts. Using rodent models, the authors found that the dopamine receptor D1 (DRD1) was selectively expressed on fibroblasts and modulated YAP/TAZ activation in the lungs. DRD1 agonists inhibited YAP/TAZ and had therapeutic effects in mouse models of lung and liver fibrosis. In lung samples from patients with pulmonary fibrosis, the enzyme responsible for dopamine synthesis was reduced, suggesting that modulating the dopaminergic pathway might be an effective strategy for treating fibrosis.


Tissue fibrosis is characterized by uncontrolled deposition and diminished clearance of fibrous connective tissue proteins, ultimately leading to organ scarring. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) have recently emerged as pivotal drivers of mesenchymal cell activation in human fibrosis. Therapeutic strategies inhibiting YAP and TAZ have been hindered by the critical role that these proteins play in regeneration and homeostasis in different cell types. Here, we find that the Gαs-coupled dopamine receptor D1 (DRD1) is preferentially expressed in lung and liver mesenchymal cells relative to other resident cells of these organs. Agonism of DRD1 selectively inhibits YAP/TAZ function in mesenchymal cells and shifts their phenotype from profibrotic to fibrosis resolving, reversing in vitro extracellular matrix stiffening and in vivo tissue fibrosis in mouse models. Aromatic l-amino acid decarboxylase [DOPA decarboxylase (DDC)], the enzyme responsible for the final step in biosynthesis of dopamine, is decreased in the lungs of subjects with idiopathic pulmonary fibrosis, and its expression inversely correlates with disease severity, consistent with an endogenous protective role for dopamine signaling that is lost in pulmonary fibrosis. Together, these findings establish a pharmacologically tractable and cell-selective approach to targeting YAP/TAZ via DRD1 that reverses fibrosis in mice.


Fibrosis contributes to 45% of all deaths in the developed world (1), with a central role in end-stage organ failure in diseases such as idiopathic pulmonary fibrosis (IPF) and liver cirrhosis (2, 3). The activation of fibroblasts to a proliferative, matrix-depositing, apoptosis-resistant phenotype represents a final common pathway driving organ fibrosis (4), highlighting the need to identify effective targets for inhibition or reversal of this fibrogenic fibroblast state. YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) are transcriptional coactivators and central effectors of the Hippo pathway (5) recently described to play pathological roles in mesenchymal cell activation and fibrosis in multiple organs, including in human lung and liver disease (611). YAP and TAZ respond to an array of mechanical and biochemical signals implicated in fibrosis, including matrix stiffness, metabolic reprogramming, transforming growth factor–β (TGFβ), myocardin-related transcription factor, and WNT signaling (1214), challenging efforts to inhibit all potential upstream drivers of their activation. More broadly, YAP and TAZ are widely expressed across multiple cell types and tissue compartments, playing important roles in numerous processes including organ growth during tissue morphogenesis, regulation of epithelial and endothelial homeostasis, and physiological tissue regeneration (1522). The widespread expression and pleiotropic roles of YAP and TAZ highlight the need to identify cell-specific strategies for inhibiting their pathological functions in disease contexts. Supporting such a strategy, recent work has demonstrated that fibroblast-selective genetic deletion of YAP/TAZ is sufficient to attenuate kidney fibrosis (8). However, pharmacologically tractable approaches for cell-specific YAP and TAZ inhibition are needed to generate more clinically relevant approaches to treat fibrotic pathologies.

Heterotrimeric GTP-binding protein (G protein)–coupled receptors (GPCRs) make up the largest family of membrane receptors in the human genome and have been prolific therapeutic targets, with their ligands accounting for >30% of all clinically approved drugs (23). In relation to fibrotic conditions, both inhibitors (2427) and activators (2830) of GPCRs have been explored for therapeutic benefit. GPCRs are linked to effector proteins from four main classes of G proteins. Recent work has highlighted that activation of receptors that couple to Gα12/13, Gαq/11, and Gαi/o stimulates YAP/TAZ nuclear translocation and transcriptional activity; in contrast, receptors that couple to Gαs inhibit YAP/TAZ nuclear localization and activity via elevation of cyclic adenosine monophosphate (cAMP) (31). GPCR expression varies across organs and even within adjacent cell types in the same tissue (32), raising the possibility that GPCR-directed therapeutics could offer a strategy for cell-selective YAP/TAZ inhibition. In particular, discovery and agonism of a GPCR selectively expressed on fibroblasts could offer a targeted approach capable of overriding multiple profibrotic stimuli through YAP/TAZ inhibition within the activated fibroblasts that drive disease progression.

Here, we identified the dopamine receptor D1 (DRD1) as a fibroblast-selective target whose agonism inhibits YAP/TAZ-mediated fibroblast activation as well as extracellular matrix (ECM) deposition and stiffening, resulting in reversal of experimental lung and liver fibrosis. DRD1 selectively couples to Gαs to promote cAMP elevation (33) and overrides both mechanical and biochemical profibrotic stimuli that promote fibroblast activation, effectively switching fibroblasts from a state that supports matrix deposition and stiffening to one that favors matrix degradation and softening. Although most commonly studied in the central nervous system, dopamine receptors are broadly expressed and play crucial roles in peripheral physiology (34, 35), although relatively little is known about the role of endogenous dopamine signaling in organs such as the lung (36). Building on our observation that DRD1 agonism promotes fibrosis resolution, we focused on DDC, the gene encoding the final step in the dopamine biosynthetic pathway, and demonstrate that its expression is decreased in the lungs of patients with IPF and inversely correlates with physiologic measures of disease severity, consistent with a protective role for endogenous dopaminergic signaling. Together, these findings identify fibroblast-selective DRD1 agonism, acting through YAP/TAZ inhibition, as an effective strategy to reverse fibroblast activation and experimental lung and liver fibrosis.


Non–cell-specific YAP/TAZ RNA interference worsens lung injury and fibrosis in mice

On the basis of the identification of YAP and TAZ as pivotal regulators of fibroblast profibrotic activation and tissue fibrosis (611), we first tested whether nonselective YAP and TAZ targeting is effective in ameliorating experimental pulmonary fibrosis. We administered YAP and TAZ small interfering RNA (siRNA) intratracheally to mice after bleomycin injury. Non–cell-specific targeting of YAP/TAZ in this context amplified fibrosis (measured by hydroxyproline assay) (Fig. 1A) and increased lung injury and vascular leakage assessed visually (Fig. 1B) and by measuring lung weight (Fig. 1C) and total protein content in bronchoalveolar lavage (BAL), illustrating the limits of such a nonselective approach. Recent work has demonstrated that YAP and TAZ regulate epithelial regeneration (17, 22) as well as endothelial homeostasis and barrier function (15, 37), raising the likelihood that YAP/TAZ function in these cellular compartments is essential to lung repair after injury. Motivated by these observations and the recent proof of concept that fibroblast-specific YAP/TAZ genetic targeting is beneficial in fibrosis (8), we sought to identify a pharmacological approach by which to target YAP and TAZ in a fibroblast-selective fashion and evaluate such an approach in preclinical models of fibrosis.

Fig. 1 Intratracheal YAP/TAZ siRNA worsens bleomycin-induced lung injury and fibrosis.

Mice were injured by intratracheal bleomycin exposure on day 0 and on day 14 treated with siRNAs targeting both YAP and TAZ. On day 21, lungs were assessed for fibrosis by measuring hydroxyproline (a surrogate for collagen deposition) (A), and injury was assessed visually (B) or by measuring lung weight (C) and total protein in bronchoalveolar lavage (BAL) fluid as markers of vascular leak (D) (n = 4 mice per group for sham and n = 5 mice per group for bleomycin). NT, nontargeting control (comparisons were made using ANOVA, *P < 0.05, ***P < 0.001, and ****P < 0.0001 versus indicated group).

DRD1 is selectively expressed on fibroblasts

Drug discovery efforts to identify direct inhibitors of the YAP/TAZ transcriptional activation complex have had limited success (38, 39). However, a variety of upstream signaling pathways that regulate YAP/TAZ cellular localization, protein stability, and their activation/inactivation (21, 4042) have been identified. Among these pathways, GPCR signaling regulates YAP/TAZ inhibition or activation in a receptor class-specific fashion (Fig. 2A) (31, 43), which led us to hypothesize that GPCRs could be attractive therapeutic targets for antifibrotic therapy based on their potential cell-specific expression and the availability of abundant pharmacologic tools to explore their function. Therefore, we profiled RNA expression of the GPCRome in multiple cell types involved in tissue fibrogenesis and repair, including primary adult human lung fibroblasts, alveolar epithelial cells, and pulmonary microvascular endothelial cells (Fig. 2B, fig. S1, and table S1). We focused on receptors that exclusively couple to Gαs (highlighted in red, Fig. 2B and fig. S1; highlighted in yellow, table S1) (33) and are expressed preferentially in fibroblasts. Of the 28 Gαs-coupled receptors, expression of the DRD1 exhibited pronounced enrichment in lung fibroblasts compared to alveolar epithelial cells (Fig. 2B) and endothelial cells (fig. S1). We confirmed abundant transcripts for DRD1 in cultured normal human lung fibroblasts and fibroblasts derived from patients with IPF and undetectable expression of DRD1 in both primary human alveolar epithelial and microvascular endothelial cells (Fig. 2C). Preferential protein expression of DRD1 was confirmed in IPF patient–derived lung fibroblasts compared to alveolar epithelial and endothelial cells by Western blotting (Fig. 2D). To extend our findings to freshly isolated lung cell populations, we sorted mouse lung tissue into epithelial, endothelial, and mesenchymal enriched fractions (fig. S2) at day 10 after bleomycin or sham treatment and assessed dopamine receptor expression across cell types (Fig. 2E and fig. S3). As in cultured human cells, we observed robust and stable expression of Drd1 (the murine homolog of DRD1) in freshly isolated mesenchymal cells but undetectable expression in other lung cell populations.

Fig. 2 s-coupled DRD1 is selectively expressed in pulmonary fibroblasts.

(A) Receptors that couple to Gαs elevate cAMP and induce phosphorylation of YAP/TAZ, blocking nuclear localization. Receptors that couple to Gαi/q/12 promote nuclear localization and activity of YAP/TAZ, as do other mechanical, metabolic, and soluble cues, through Rho-kinase (ROCK) and other pathways. (B) GPCR expression profile of primary cultured human alveolar epithelial cells and normal human pulmonary fibroblasts. Red points indicate GPCRs that selectively couple to Gαs. Blue lines indicate 100-fold preferential expression. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (C) DRD1 expression in cultured non–IPF-associated fibroblasts (FBs) (n = 5 biologically independent samples), IPF patient–derived fibroblasts (n = 5 biologically independent samples), normal human alveolar epithelial cells (NHAEpC) (n = 3 biologically independent samples), and normal human microvascular endothelial cells (NHMVEC) (n = 3 biologically independent samples); all passages are six or less. NS, not significant; ND, not detected. (D) Western blot protein expression of the D1 dopamine receptor from IPF patient–derived fibroblasts, normal human alveolar epithelial cells, and normal human microvascular endothelial cells (n = 3 biologically independent samples). (E) Expression of Drd1 in freshly isolated mouse lung fibroblasts, epithelial cells (EpCs), and endothelial cells (ECs). Lung from sham or day 10 after bleomycin-treated Col1a1-GFP–expressing mouse was enzymatically digested and then sorted for markers of epithelial cells (validated by Epcam expression), endothelial cells (validated by Pecam1 expression), and fibroblasts (validated by Col1a1 expression), followed by RNA isolation and quantitative polymerase chain reaction for Drd1 (n = 3 mice per group) (comparisons were made using ANOVA, **P < 0.01 versus indicated group).

DRD1 agonism selectively inhibits YAP/TAZ nuclear localization in fibroblasts

Dopamine receptors have been studied for decades, providing a rich library of receptor ligands. Dopamine receptors are divided into two families: Gαs-coupled D1-like (DR1 and DR5) and Gαi-coupled D2-like (DR2 to DR4). To identify an appropriate pharmacological lead, we tested 33 previously defined dopaminergic agonists with varying D1/D2 selectivity for their ability to inhibit YAP/TAZ nuclear localization in IPF fibroblasts (Fig. 3A). Cells plated on stiff matrix (plastic) and lacking cell contact inhibition exhibit abundant nuclear localization of YAP/TAZ due to mechanotransduction (6, 44). Of the agonists tested, all D1-selective, full agonists reduced YAP/TAZ nuclear localization, with dihydrexidine (DHX) as the most effective, as did the nonselective biological ligand dopamine (Fig. 3A, table S2, and fig. S4). DHX elevated cAMP (Fig. 3B) and promoted YAP Ser127 phosphorylation (Fig. 3C), consistent with the previously defined mechanism whereby YAP/TAZ nuclear localization is attenuated by cAMP-dependent phosphorylation of serine residues, promoting YAP/TAZ cytoplasmic retention or degradation (31, 43). DHX was effective at inhibiting YAP/TAZ nuclear localization across a panel of mesenchymal cell types, including cardiac and dermal fibroblasts and hepatic stellate cells (HSCs) (Fig. 3D), suggesting potentially broad relevance of this ligand for inhibiting mesenchymal cell YAP and TAZ activation. In contrast to these observations, DHX had no effect on YAP/TAZ localization in subconfluent pulmonary epithelial and endothelial cells (Fig. 3, D and E, and fig. S5), consistent with the absence of detectable transcripts for DRD1 in these lung cell types. In addition, DHX treatment selectively repressed expression of established YAP/TAZ target genes (4548) in fibroblasts but not lung epithelial or endothelial cells (Fig. 3E and fig. S6A). Conversely, agonism of the prostaglandin EP2 receptor, a Gαs-activating receptor expressed in all three cell types (fig. S7A), reduced localization of YAP/TAZ and repressed expression of YAP/TAZ target genes across all cell types (Fig. 3F and fig. S6B), highlighting the cell-selective nature of the DHX effects on fibroblasts. Although EP2 receptor stimulation is known to exert antifibrotic effects on lung fibroblasts, the potency of such effects is diminished in IPF (49). DHX-mediated inhibition of YAP/TAZ nuclear localization was equally potent in normal lung fibroblasts and those derived from patients with IPF, unlike EP2 receptor activation (fig. S7B) (49). Thus, DHX exhibited both cell selectivity and preserved potency in targeting YAP/TAZ in IPF fibroblasts.

Fig. 3 DRD1 agonism selectively blocks YAP/TAZ nuclear localization in fibroblasts.

(A) IPF patient–derived lung fibroblast cells treated 2 hours before fixation with a library of diverse, mixed selectivity, dopaminergic agonists (10 μM) (n = 4 biologically independent samples). Representative image: 10 μM DHX. Percent nuclear localization of YAP/TAZ was determined using automated imaging software. Scale bars, 100 μm. Box plots represent range and mean. DAPI, 4′,6-diamidino-2-phenylindole. (B) cAMP measured in IPF patient–derived fibroblasts treated for 20 min with the indicated concentration of DHX or forskolin (10 μM) (n = 3 biologically independent samples). (C) Total and phospho-Ser127 YAP responses to the Rho-kinase inhibitor Y27632 (20 μM), forskolin (10 μM), or DHX (10 μM). IMR-90 lung fibroblasts [n = 3 independent experiments; comparisons were made using ANOVA, ***P < 0.001 versus 0.1% dimethyl sulfoxide (DMSO) vehicle control]. (D) YAP/TAZ nuclear localization response to DHX in fibroblasts from multiple organs: IPF patient–derived lung fibroblasts, HSCs, human adult cardiac fibroblasts, human dermal fibroblasts, and human lung alveolar epithelial or human pulmonary microvascular endothelial cells (n = 3 biologically independent samples) (comparisons were made using t test, ***P < 0.001 versus 0.1% DMSO vehicle control). (E and F) IPF patient–derived lung fibroblasts, lung alveolar epithelial (NHAEp), and endothelial (NHMVE) cells treated with DHX (E) or with butaprost (EP2 receptor agonist) (F). YAP/TAZ localization was determined after 2 hours (left), and expression of YAP/TAZ target genes was determined at 24 hours (right) (n = 3 biologically independent samples) (comparisons were made using ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus the corresponding control-treated cells). Orange asterisks relate to fibroblast data; black asterisks relate to epithelial cell data, and blue asterisks relate to endothelial cell data.

To confirm the receptor specificity of DHX effects, we used both RNA interference and receptor antagonist approaches. We found that the inhibition of YAP/TAZ nuclear localization, elevation of cAMP, and repression of YAP/TAZ target genes by DHX could all be attenuated using two structurally independent D1 receptor-selective antagonists, as well as by treating cells with DRD1-siRNA (fig. S8).

DRD1 agonism reverses profibrotic phenotypes and promotes matrix degradation

Fibrosis is thought to occur through a combination of fibroblast activities, including activation to a contractile myofibroblast state, as well as persistent imbalances in both proliferation/apoptosis and matrix deposition/degradation. To test whether dopamine receptor agonism alters contractile activation, we treated IPF patient–derived lung fibroblasts with the same library of 33 dopaminergic agonists in the presence of TGFβ for 72 hours (Fig. 4A and table S3) and quantified expression of the contractile myofibroblast marker, α–smooth muscle actin (αSMA). In agreement with the results observed for the inhibition of YAP/TAZ nuclear localization (Fig. 3A), D1 receptor full agonists, including DHX, were highly effective in blocking αSMA expression, as was the nonselective biological ligand dopamine. Functionally, traction force microscopy confirmed that DHX dose-dependently reduced the contractile forces generated by fibroblasts (Fig. 4B).

Fig. 4 DHX reverses fibroblast matrix deposition, contraction, and stiffening.

(A) IPF patient–derived lung fibroblast cells treated for 72 hours before fixation with a library of diverse, mixed selectivity, dopaminergic agonists (1 μM) + TGFβ (n = 4 biologically independent samples, different patient samples). Representative image: 1 μM DHX. αSMA intensity was determined using automated imaging software. Box plots represent range and mean. Scale bars, 100 μm. (B) IPF fibroblast traction responses to DHX (n = 10 cells per condition). The minimum to maximum, quartile range, and median of cell tractions (comparisons were made using ANOVA, ****P < 0.0001 and *P < 0.05 versus 0.1% DMSO vehicle control) are shown. RMS, root mean square. (C) ECM deposited by IPF patient–derived fibroblasts prestimulated with TGFβ (2 ng/ml) for 48 hours and then treated with DHX + TGFβ (2 ng/ml) for additional 24 hours (n = 3 biologically independent samples) (comparisons were made using ANOVA, ****P < 0.0001, ***P < 0.001, and **P < 0.01 versus 0.1% DMSO vehicle control). (D) ECM cross-linking and degradation-associated gene programs measured in IPF fibroblasts treated for 24 hours with TGFβ (2 ng/ml) ± 10 μM DHX or YAP and TAZ siRNA (>90% knockdown) (n = 3 biologically independent samples). Heat map indicates percent change relative to unstimulated controls. (E) Stiffness of IPF patient–derived fibroblasts and their cell-derived matrices measured by AFM microindentation after 72 hours and then again after treatment ± 10 μM DHX for additional 72 hours (n = 5 biologically independent samples) (comparisons were made using t test, *P < 0.05 versus 0.1% DMSO vehicle control).

Focusing next on proliferation/apoptosis, we sought to assess the potential power of D1 receptor activation as a means to broadly counteract proliferative signals. We tested DHX in parallel with multiple stimuli, including GPCR ligands and growth factors known to promote fibrosis (50, 51). Under confluent culture conditions, we observed low YAP/TAZ nuclear localization that was elevated in response to endothelin-1 (ET-1), lysophosphatidic acid (LPA), and serotonin [5-hydroxytryptamine (5-HT)], all GPCR ligands implicated in the promotion of fibrosis (5255), as well as profibrotic growth factors TGFβ and connective tissue growth factor (CTGF). DHX blocked nuclear localization of YAP/TAZ in response to all of these ligands (fig. S9A). Functionally, we observed that DHX broadly inhibited the proliferative effects of LPA, ET-1, TGFβ, and CTGF in IPF fibroblasts (fig. S9, B and C) but was not toxic at any concentration tested (fig. S9D), as measured by two different cell viability assays. These results confirm that a variety of profibrotic GPCR ligands and growth factors positively influence both YAP/TAZ nuclear localization and fibroblast proliferation and identify DHX as an effective strategy for broadly inhibiting proliferative effects downstream of these diverse stimuli.

Turning to matrix deposition, we found that a 24-hour treatment with DHX dose-dependently reduced TGFβ-stimulated accumulation of collagen I and fibronectin (Fig. 4C and fig. S10). To assess whether this effect depended on the inhibition of YAP/TAZ, we used NIH 3T3 cells that stably express a doxycycline-inducible, constitutively active, mutant TAZ (TAZ4SA) (6). In these cells, DHX failed to affect profibrotic gene expression or ECM accumulation (fig. S11), demonstrating that YAP/TAZ serine phosphorylation and inhibition are essential to the antifibrotic effects of DHX.

We and others have recently shown that activated fibroblasts self-amplify the fibrotic response by increasing matrix stiffness, which promotes mechanoactivation of quiescent fibroblasts in a positive feedback mechanism (5658). We thus asked whether DHX or YAP/TAZ knockdown influenced expression of key matrix cross-linking and degradation genes (Fig. 4D and fig. S12). Both DHX and YAP/TAZ siRNAs broadly reversed TGFβ-mediated expression of matrix cross-linking genes and increased expression of key genes associated with matrix degradation and clearance in IPF fibroblasts. To directly test the effects of DHX on matrix deposition and stiffening, we developed an in vitro cell-derived matrix remodeling assay. We first plated IPF patient–derived fibroblasts at confluence (Fig. 4E) and stimulated them with TGFβ and ascorbic acid to promote matrix synthesis and deposition. After 72 hours, we measured the stiffness of the cells and their cell-derived matrix using atomic force microscopy (AFM). To test the ability of DHX to induce cell-mediated matrix remodeling, we maintained the TGFβ and ascorbic acid ± DHX for an additional 72 hours before probing the matrix again with AFM. In the absence of DHX treatment, the cells and matrix continued to stiffen over time. In contrast, DHX treatment reversed this trend and reduced the observed stiffness (Fig. 4E). Together, these results demonstrate that DRD1 agonism results in a shift in fibroblast program away from a contractile, proliferative, and matrix-depositing state toward a matrix-degrading and softening state potentially linked to fibrosis resolution.

DRD1 agonism reverses experimental lung and liver fibrosis

To test the therapeutic efficacy of DHX treatment in models of experimental tissue fibrosis, we again used the bleomycin model of pulmonary fibrosis. Mice were administered bleomycin intratracheally at day 0. We then waited until day 10 for injury and inflammation to subside and fibrosis to be ongoing before randomizing into two groups: one receiving DHX for 14 days [5 mg/kg once daily intranasally (i.n.)] and the other receiving vehicle control. The DHX-treated group lost less weight than the vehicle control group (Fig. 5A). Histologically, the DHX-treated group exhibited nearly complete reversal of established lung fibrosis compared to the vehicle control group, as assessed by a pathologist blinded to the treatments (Fig. 5, B and C). Total collagen in the lungs of DHX-treated mice was not different from sham-treated mice and reduced compared to vehicle control mice (Fig. 5D). Bleomycin exposure enhanced transcripts for profibrotic genes, all of which were attenuated by DHX treatment (Fig. 5E). Bleomycin also increased staining for αSMA in the lungs, and this was reversed by DHX treatment (Fig. 5F). To assess whether DHX adversely affected lung remodeling in the absence of fibrosis, we exposed control mice to DHX following an identical time course and route of exposure. The lungs of sham DHX mice did not differ from those of control mice using any of these measurements (fig. S13).

Fig. 5 DHX therapeutically reverses bleomycin-induced pulmonary fibrosis.

(A) Weight change as a result of bleomycin-induced lung injury ± DHX. Female mice were intratracheally administered bleomycin on day 0; DHX treatment was initiated on day 10 [DHX (5 mg/kg i.n., daily)] and continued until day 24 (comparisons were made using t test, *P < 0.05 versus bracket indicated group). (B and C) Hematoxylin and eosin staining to visualize architectural changes (40× objective). Paraffin-embedded lung sections were stained and scored using the Ashcroft method. (D) Lung tissue was biochemically analyzed for collagen abundance using the hydroxyproline assay. (E) Changes in profibrotic gene expression in whole-lung homogenates. (F) Immunofluorescence imaging of lung sections for αSMA. Representative section from each group (4× objective) is shown. αSMA intensity was quantified by automated image analysis. Scale bars, 1000 μm. Sham control, n = 15; bleo control, n = 17; bleo DHX, n = 17 (from two independent experiments) [(C to F) comparisons were made using ANOVA, ****P < 0.0001, **P < 0.01, and *P < 0.05 versus bracket indicated group].

Our original selection of DRD1 as a target was based on the goal of selectively targeting YAP/TAZ in lung fibroblasts. To assess the cell specificity of in vivo DHX treatment, we administered bleomycin intratracheally to mice at day 0 and then waited until day 10 for injury and inflammation to subside and fibrosis to be ongoing before randomizing into two groups: one receiving DHX for short treatment (5 mg/kg, i.n.) and the other receiving vehicle control. Mice were treated 24 and 2 hours before either cell isolation from the lungs by fluorescence-activated cell sorting (FACS) or immunofluorescence imaging (Fig. 6A). We implemented the same FACS strategy as in Fig. 2 and measured changes in well-established YAP/TAZ target genes as in our in vitro studies (Fig. 3, E and F, and fig. S6). Freshly sorted lung fibroblasts, but not lung epithelial or endothelial cells, exhibited DHX-dependent decreases in Yap1, Ccne1, Axl, and Cyr61 (Fig. 6, A and B). To further confirm DHX-mediated YAP/TAZ inhibition in lung fibroblasts in situ, we assessed YAP/TAZ nuclear localization in Col1a1-GFP–positive cells by confocal microscopy. Fibroblasts in DHX-treated lungs exhibited reduced YAP/TAZ nuclear localization relative to vehicle-treated controls, further supporting the D1 receptor as a mediator of YAP/TAZ activation specifically targetable on lung-resident fibroblasts (Fig. 6C).

Fig. 6 DHX selectively blocks expression of YAP/TAZ target genes in lung fibroblasts in vivo.

(A) Mice received bleomycin intratracheally at day 0 and two doses of DHX or vehicle control 2 and 24 hours before collecting lungs at day 11 for flow sorting of fibroblasts, epithelial cells, and endothelial cells. (B) Expression of YAP/TAZ target genes from freshly isolated cells (n = 8 mice per group) (comparisons were made using t test, **P < 0.01 and *P < 0.05 versus indicated group). (C) Representative confocal microscopy images of YAP/TAZ nuclear localization in GFP-positive lung fibroblasts shown in both two-dimensional (2D) and 3D projections.

On the basis of the efficacy of DHX in experimental lung fibrosis and in attenuating YAP/TAZ nuclear localization across an array of cultured mesenchymal cell types including HSCs (Fig. 3D), we sought to extend our findings to liver fibrosis. Previous studies have demonstrated a profibrotic role for hepatocyte TAZ activation (59) and limited beneficial effects of global YAP/TAZ inhibition in experimental liver fibrosis (7, 9). However, YAP/TAZ are essential to liver regeneration (20), and nonspecific YAP knockdown in the liver promotes hepatocyte necrosis (60), highlighting again the need to interrogate complementary targets upstream from YAP/TAZ such as the D1 dopamine receptor. We profiled the GPCRome of cultured HSCs and hepatocytes and confirmed preferential expression of DRD1 in HSCs (Fig. 7, A and B, and table S1), echoing our findings in the lung. We then confirmed the ability of DHX to reduce baseline and TGFβ-mediated fibrogenic activation in HSCs (Fig. 7C). Last, we tested the efficacy of DHX in the bile duct ligation (BDL) model of cholestatic liver fibrosis. BDL was performed at day 0, and treatment with DHX or vehicle began at day 7 and continued until day 21. DHX improved histological fibrosis caused by BDL, reduced αSMA, and exhibited a trend toward reduced hydroxyproline (Fig. 7, D and E), extending the efficacy of our GPCR-based approach to experimental liver fibrosis. As anticipated, DHX had no effect on indices of liver injury, highlighting its HSC-targeted mode of action (fig. S14).

Fig. 7 DHX reverses HSC activation and hepatic fibrosis.

(A) GPCR expression profile of primary cultured human HSCs and hepatocytes. Red points indicate GPCRs that selectively couple to Gαs. Blue lines indicate 100-fold preferential expression. (B) DRD1 expression in HSCs (validated by PDGFRA expression) relative to hepatocytes (Heps; validated by ALB expression) (n = 3 biologically independent samples) (comparisons were made using t test, ****P < 0.0001 versus indicated group). (C) DHX effects on TGFβ-mediated HSC activation in vitro measured by αSMA, fibronectin, and collagen I Western blots. TGFβ (2 ng/ml) 48 hours ± 10 μM DHX final 24 hours (n = 3 to 5 independent experiments) (comparisons were made using ANOVA, ***P < 0.001, **P < 0.01, and *P < 0.05 versus indicated group). HSC70, heat shock cognate 71 kDa protein. (D and E) On day 7 after BDL surgery, male and female mice began receiving DHX (5 mg/kg intraperitoneally once daily) until day 21 when livers were assessed for fibrosis. Representative Sirius red (D)– and αSMA (E)–stained sections (4× objective) and quantification of collagen by Sirius red area and hydroxyproline (D) and αSMA by immunofluorescence (E) are shown. αSMA intensity was quantified by automated image analysis. Scale bars, 1000 μm. For αSMA and Sirius red, sham control n = 7, BDL control n = 10, sham DHX n = 8, and BDL DHX n = 13. For hydroxyproline, sham control n = 9, BDL control n = 12, sham DHX n = 8, and BDL DHX n = 17, both collected from two independent replicate experiments (comparisons were made using ANOVA, ***P < 0.001 and **P < 0.01 versus indicated group).

3,4-dihydroxyphenylalanine decarboxylase expression is diminished in IPF

As introduced above, the dopamine receptor family has five members from two classes: D1-like (DRD1 and DRD5) coupling to Gαs and D2-like (DRD2 to DRD4) coupling to Gαi. DRD1 is the dominant receptor in lung fibroblasts (fig. S3 and table S1); hence, the fibroblast response to the nonselective biological ligand dopamine is similar to that with DHX (Figs. 3A and 4A, and fig. S15), suggesting that local dopamine production in the lung could provide an endogenous antifibrotic signal. DOPA (3,4-dihydroxyphenylalanine) decarboxylase is the enzyme responsible for the final biosynthesis of dopamine from l-DOPA precursor and is classically known to be diminished in brain regions of patients with Parkinson’s disease (61). To determine whether genes associated with dopaminergic signaling are differentially expressed in the lungs of patients with IPF compared to controls, we analyzed expression of DDC (encoding human DOPA decarboxylase) and DRD1 (encoding human DRD1). Using the Lung Genomics Research Consortium ( tissue microarray dataset, we compared expression from 134 IPF and 108 controls. The demographic and clinical characteristics of these subjects have been previously described in detail (62) and are summarized in table S4. The relative expression of DDC transcripts in IPF lungs were decreased compared to the control lungs (Fig. 8A), whereas DRD1 transcripts were not different between IPF and control lungs (Fig. 8B). To confirm altered expression of DOPA decarboxylase in IPF lung tissue at protein level, we compared DDC protein expression using explanted lung tissues from patients with IPF and donor lungs that were not suitable for transplantation. As shown in Fig. 8 (C and D), the expression of DDC protein was reduced in IPF lungs compared to donor lungs. In addition to the 52-kDa predicted full-length protein, the predominant form of DDC protein expressed in the lung tissues was ~47 kDa, potentially reflecting alternative splicing (63). The expression of both the 52-kDa and the lower–molecular weight variant in IPF were reduced (53 and 60% compared to donor lungs) (Fig. 8D). Therefore, we conclude that both DDC transcripts and DDC protein are reduced in IPF lungs. We next tested whether the changes in DDC gene expression in IPF correlate with pulmonary function. Decreased DDC transcripts were correlated with worsening of both forced vital capacity (FVC; a measure of lung compliance) and the lung’s gas diffusing capacity [as measured by the diffusing capacity of the lungs for carbon monoxide (DLCO); Fig. 8, E and F]. Last, we confirmed that DDC transcripts also inversely correlated with the gender-age-pulmonary (GAP) score (64), a validated mortality prediction tool in IPF (fig. S16). To extend these observations to liver fibrosis, we analyzed a smaller published dataset of transcriptional profiles from liver samples of 7 controls and 15 individuals with alcoholic hepatitis (65). However, in this cohort, DDC expression was not statistically different between controls and individuals with alcoholic hepatitis (fig. S17). Together, these results demonstrate that expression of DDC, encoding the final enzyme responsible for dopamine synthesis, is diminished in the lungs of patients with IPF, and decreased DDC expression correlates with worsened lung function and higher predicted mortality. Connecting these results to the beneficial effects of DRD1 agonism seen in our experimental fibrosis models supports the potential physiological relevance of the dopaminergic system as a therapeutic target in human fibrotic pathologies.

Fig. 8 DOPA decarboxylase is decreased in IPF and correlates with worsening disease severity.

(A and B) Expression of DDC and DRD1 was queried from microarray analyses of IPF (n = 134) and control (n = 108) lungs. Each data point represents expression from an individual. Bars indicate mean and SD (comparisons were made using t test; P values are indicated in the figure panels). (C) Western blotting to detect DDC protein expression in whole-lung homogenates from IPF (n = 10) and control donor (n = 11) lungs. (D) Quantification of upper and lower bands from Western blots, normalized to GAPDH. Bars indicate mean and SD (comparisons were made using t test; P values are indicated in the figure panels). (E and F) Univariate analysis of the correlation of DDC expression with forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) assessed using the Pearson’s correlation coefficient (r). Each data point represents expression and lung function (expressed a percentage predicted based on age, sex, and ideal body weight) from an individual (P values are indicated in the figure panels).


Fibrotic diseases remain a major medical burden with limited treatment options (2). Our work highlights DRD1 as a potential therapeutic target for lung and liver fibrosis. DRD1 agonism inactivates YAP/TAZ and switches activated fibroblasts from a contractile, proliferative, and matrix-depositing fibrogenic state to a proresolving matrix-degrading state. DRD1 is preferentially expressed on lung and liver mesenchyme relative to other structural cells of these organs, providing a cell-selective approach that preserves YAP/TAZ function in epithelial and endothelial compartments important for injury resolution and tissue repair (1521). Whereas our focus on DRD1 emerged from primary studies in lung fibroblasts, comparison of the GPCRome in hepatocytes and HSCs identified additional attractive targets, including the serotonin receptor 5-HT7, and limited published evidence suggests that 5-HT7 agonism is also beneficial in liver fibrosis (28). Thus, our approach may be expandable to include additional GPCR candidates and consideration of a similar approach in other organs, allowing identification of therapeutic targets specific to fibroblasts in other tissues affected by fibrotic pathologies, such as kidney, heart, pancreas, and skin.

Activated GPCRs signal through a multitude of downstream pathways including altered YAP/TAZ activation (66). In our studies, overexpression of mutant TAZ4SA was sufficient to override the antifibrotic effects of DRD1 agonism, indicating that YAP/TAZ inactivation is an essential downstream component of fibroblast signaling via this receptor, an observation echoed in recent observations of an essential role for YAP/TAZ inactivation downstream of the prostacyclin receptor (67). Abundant published evidence also supports the concept that GPCR responses, both those that stimulate and those that inhibit profibrotic fibroblast activation, mirror effects on YAP/TAZ activation or inhibition (27, 68, 69). For example, LPA, ET-1, and serotonin have all been implicated in fibroblast activation and fibrosis, and all are competent to enhance fibroblast YAP/TAZ nuclear localization. In contrast, stimulation of numerous Gαs-coupled GPCRs ablate YAP/TAZ activation (31), and several have emerged as potential antifibrotic targets, including relaxin, prostaglandin, and adenosine receptors (7072). Accumulating evidence suggests that Gαs-coupled receptor loss may be a common occurrence in pathological fibrosis because both prostaglandin EP2 (73, 74) and relaxin family peptide receptor 1 (RXFP1) (75) receptors have been reported to decline in expression in patients with IPF. In the case of DRD1, our data demonstrate that the receptor remains expressed in the lung and on fibroblasts, but we see decreased expression of DOPA decarboxylase, the enzyme responsible for dopamine production, at both the transcript and protein levels in human IPF, suggesting a loss of local endogenous dopaminergic Gαs signaling. Our findings specifically highlight DRD1 agonism as a highly attractive therapeutic modality in IPF because the receptor remains expressed in diseased lung fibroblasts and available for agonist targeted therapy.

Endogenous dopaminergic signaling in the lung and liver has received relatively little attention, although local dopamine production has been implicated in fluid clearance during lung injury (76, 77). Efforts to measure local dopamine in the lung and liver may be helpful as biomarkers to understand fibrosis resolution and patients who might benefit from DRD1 targeted therapeutics, as exemplified by the variability in DDC expression among individuals with IPF and alcoholic hepatitis. As a circulating biomarker, dopamine may provide less useful information because it is rapidly sulfonated by sulfotransferase family 1A member 3 (SULT1A3) in multiple tissues and circulates in a predominantly inactive form (78). SULT1A3 expression is markedly reduced during development toward adulthood in liver and lung, supporting the plausibility of dopamine acting as a local paracrine mediator of fibroblast biology in these tissues (79). Our work highlights the need to further verify the local action and cellular source(s) of endogenous dopamine production during tissue repair and fibrosis while establishing the therapeutic potential of exogenously targeting this pathway.

Last, our results raise the intriguing possibility that reprogramming of activated fibrotic fibroblasts into a matrix-degrading phenotype may represent a major cellular mechanism during normal resolution of fibrosis, particularly in response to signaling through Gαs-coupled receptors and YAP/TAZ inactivation. Although the focus of fibrosis resolution research has largely centered on macrophages (80, 81), fibroblasts also express key genes implicated in matrix degradation and are competent to degrade fibrillar collagens (80, 82). Treatment with either DHX or YAP/TAZ siRNA reduced expression of matrix cross-linking genes and enhanced expression of genes that code for collagen-degrading enzymes cathepsin K and matrix metalloproteinase 14, both of which have been shown to reduce collagen accumulation in experimental fibrosis models (8386). These findings and the accompanying change in cell/ECM stiffness that we observed after DRD1 agonist treatment raise the possibility that fibroblasts may be active participants in normal matrix resorption after tissue injury. Whereas recent efforts to target fibroblasts have focused on removing senescent or activated cells through targeted clearance (87, 88), our findings add another attractive possibility: eliciting fibroblast’s native fibrosis-resolving capacities through receptor-mediated stimulation.

An important limitation and question raised by our study is whether such matrix-degrading capacities of fibroblasts can be effective in the setting of established human fibrotic pathologies, particularly because the extent of collagen cross-linking found in human disease is not likely captured in the relatively short-term models tested here. An additional limitation to our study is that we have not directly measured endogenous dopamine production or signaling in the lung or liver. Hence, further effort will be needed to clarify the functional roles of dopamine within the context of tissue injury, repair, and fibrosis. Last, our analysis of dopamine receptor expression was limited to cells sorted by classical, but relatively broad, lineage markers. Additional consideration of the cellular subpopulations within repairing and fibrotic tissues will be important to further define the cellular targets of D1 agonism in the lung and liver.

Together, our findings demonstrate that GPCR agonism can be used to pharmacologically target YAP and TAZ in select cell populations to exert beneficial effects on tissue fibrosis. The safety and therapeutic window for DHX and other dopaminergic therapies in human central nervous system indications are well known (89, 90), with the most prevalent side effect being hypotension, an effect largely ameliorated in later studies (91). Development of peripherally restricted and organ-targeted approaches should be prioritized so that D1 receptor agonism could be safely evaluated for the treatment of tissue fibrosis in the lung, liver, and other organs. This approach might represent a substantial step forward in developing effective therapies for patients with fibrotic diseases.


Study design

The goal of this study was to identify a strategy to selectively inhibit YAP and TAZ activity in resident mesenchymal cells associated with lung and liver fibrosis. We identified the DRD1 as a putative target to treat these diseases and tested the D1 receptor agonist DHX in vitro and in vivo. In cell-based assays, we treated lung fibroblasts and HSCs with DHX and observed a pronounced shift in their phenotype from profibrotic to fibrosis resolving. For in vivo mouse studies, intratracheal bleomycin and BDL were chosen as well-established and relevant models of experimental lung and liver fibrosis, respectively. Sample sizes were calculated by power analysis based on previous experience and feasibility. For lung fibrosis experiments testing DHX, n ≥ 15 to 17 mice per group were used to achieve statistical significance, and for liver fibrosis experiments, n ≥ 7 to 13 mice per group were used. Mice were randomly assigned to treatment groups. Biochemical and histological outcomes were analyzed with the investigator blinded to the treatment groups, and no animals were excluded as outliers from the reported dataset. All in vitro and in vivo experiments were performed in two to four technical replicates. The number of biologically independent samples and/or biologically independent experiments is identified in each figure legend. Detailed methods for in vitro and tissue analyses are provided in the Supplemental Materials.


Eight-week-old female and male C57BL/6 mice were purchased from the Jackson laboratory. Col1a1-GFP (green fluorescent protein) transgenic mice were generated as previously described (92). All animal experiments testing DHX were carried out under protocols approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC). In the initial in vivo siRNA study (Fig. 1), adult male age-matched C57BL/6N mice at 6 to 8 weeks of age were purchased from the National Cancer Institute–Frederick Mouse Repository. These experiments were performed in accordance with the National Institutes of Health guidelines and protocols approved by the Massachusetts General Hospital Subcommittee on Research Animal Care.

Bleomycin mouse studies

Six- to 8-week-old mice were anesthetized with ketamine and xylazine before exposure of the trachea. Lung fibrosis was induced by intratracheal injection of bleomycin (50 μl at 1.2 U/kg) or phosphate-buffered saline (PBS; as control) on day 0. After 14 days, siRNA duplexes targeting mouse Yap (L-046247-01-0005) or Taz (L-058248-01-0005) mRNA (Dharmacon) or nontargeting control siRNA was administered in vivo by intratracheal instillation at a single dose of 25 μg (each siRNA) per mouse and 50 μg of nontargeting. On day 21, mice were euthanized, and lungs were harvested for collagen determination and biochemical analyses. To obtain BAL samples for total protein concentration determination, lungs were lavaged with six 0.5-ml aliquots of PBS. BAL samples were centrifuged at 3000g for 20 min at 4°C, and we transferred the supernatants to siliconized low-binding Eppendorf tubes (PGC Scientific) for subsequent analysis. Total protein concentration of the BAL fluid was determined using BCA Protein Assay Kit (Pierce). In the DHX treatment studies, 8-week-old female C57BL/6 mice (Fig. 5) or 8-week-old female Col1a1-GFP transgenic mice (Fig. 6), lung fibrosis was induced with bleomycin (Fresenius Kabi) delivered intratracheally with 1.2 U/kg to the lungs using MicroSprayer Aerosolizer (Penn-Century). The sham-treated mice received sterile 0.9% saline instead, using identical methods. Mice were weighed every 24 hours, and both groups were then randomized at day 10 into DHX and control treatment groups, matching for the degree of weight change. DHX (5 mg/kg) was administered daily intranasally dissolved in surfactant (Infasurf), which has previously shown to aid in spreading to pulmonary alveoli (93) for 14 days (Fig. 5) or 1 day, dosed 24 and 2 hours before lung collection (Fig. 6). The control groups of mice received the equivalent vehicle dose of surfactant. After the final DHX treatment, mice were euthanized, and the right lungs were inflated with 4% paraformaldehyde and further incubated in 4% paraformaldehyde for 24 hours before processing for paraffin embedding. The left lobe of the lung was snap-frozen in liquid nitrogen for RNA isolation and hydroxyproline assay (Fig. 5) or used for FACS (Fig. 6).

Bile duct ligation

BDL was performed as previously described (94). Briefly, 8- to 10-week-old male and female C57BL/6N mice underwent either BDL or sham surgery. Mice were anesthetized on day 0 following the IACUC protocol, and the bile duct was ligated using sterile 3/0 silk ligatures. Sham surgery was performed by passing a silk ligature under the bile duct. Starting on day 7, DHX (5 mg/kg) or vehicle control was administered daily intraperitoneally for 14 days. After the final DHX treatment, mice were euthanized, and the livers were harvested for analysis of fibrosis. Liver enzymes were analyzed by loading 100 μl of serum in a Mammalian Liver enzymes rotor (Abaxis) and read by VetScan 2.0.

Lung tissue gene expression analysis

Publicly available data from the Lung Genomics Research Consortium ( were queried for expression of dopamine signaling–related genes from the lungs of 134 patients with IPF and from 108 donor controls. RNA isolation and microarray procedures have been described previously (95, 96). These data and methods are available in the Gene Expression Omnibus database (accession number GSE47460). The clinical characteristics of the patients have been published previously (62).


In experiments comparing groups of three or more, groups were compared by one-way analysis of variance (ANOVA) with Tukey’s post hoc comparison after confirming that data displayed a normal distribution. In experiments comparing two groups, groups were compared using unpaired t test with Welch’s correction. Results are expressed throughout as means ± SEM or with box-and-whisker plots showing minimum to maximum, quartile, and median. Statistical tests for Figs. 1 to 7 were carried out using GraphPad Prism 7 with statistical significance defined as P < 0.05. For human lung tissue gene expression analyses (Fig. 8), we used the Mann-Whitney test to determine the difference in expression of DDC and DRD1 between IPF and controls and DDC protein between explanted IPF and donor lungs. Univariate analysis was performed by using the Pearson’s correlation coefficient of gene expression data with FVC and DLCO. These analyses were performed by using Stata 14.0 (StataCorp). GAP function scoring was performed on the basis of previously established criteria (64).


Materials and Methods

Fig. S1. GPCR expression profile of primary cultured human pulmonary microvascular endothelial cells and normal human pulmonary fibroblasts.

Fig. S2. FACS gating strategy to isolate mouse pulmonary fibroblasts, epithelial cells, and endothelial cells from Col1a1-GFP transgenic mice.

Fig. S3. Expression of Drd1-4 in freshly isolated mouse lung fibroblasts, epithelial cells, and endothelial cells.

Fig. S4. DHX inhibits nuclear localization of YAP and TAZ.

Fig. S5. Representative YAP/TAZ localization in IPF-derived fibroblasts, alveolar epithelial cells, and pulmonary microvascular endothelial cells treated with DHX.

Fig. S6. Expression of additional YAP/TAZ target genes in fibroblasts, epithelial cells, and endothelial cells treated with D1 and EP2 receptor agonists.

Fig. S7. Prostaglandin E2 receptor expression in human lung fibroblasts, epithelial cells, and endothelial cells and loss of potency in IPF patient–derived lung fibroblasts.

Fig. S8. DHX activity is dependent on DRD1 receptor.

Fig. S9. DHX represses lung fibroblast proliferation without acute cytotoxicity.

Fig. S10. DHX reduces collagen I and fibronectin protein expression.

Fig. S11. DHX inhibits profibrotic gene expression and matrix deposition through inhibition of YAP/TAZ.

Fig. S12. DHX and YAP/TAZ siRNA modulate matrix cross-linking and degradation gene programs.

Fig. S13. DHX alone does not affect lung matrix content or profibrotic gene expression.

Fig. S14. Liver function tests in BDL experiments.

Fig. S15. Dopamine promotes antifibrotic effects.

Fig. S16. DDC transcripts inversely correlate with the stage of GAP function score, a clinically validated tool to predict 1-year mortality.

Fig. S17. DDC expression in subjects with alcoholic hepatitis.

Table S1. GPCR expression profiles from primary human lung fibroblasts, epithelial cells, endothelial cells, HSCs, and hepatocytes.

Table S2. Dopaminergic agonist library effects on YAP/TAZ localization.

Table S3. Dopaminergic agonist library effects on αSMA expression.

Table S4. Clinical and demographic characteristics of the Lung Genomics Research Consortium cohort.

Table S5. Polymerase chain reaction primers used in this study.

Data file S1. Raw data (provided as separate Excel file).

References (97106)


Acknowledgments: We acknowledge the guidance and assistance provided by the Mayo Clinic Office of Translation to Practice, housed within the Center for Clinical and Translational Science, supported by CTSA grant number UL1 TR002377 from the National Center for Advancing Translational Sciences. Funding: Support was provided by an ALA Senior Research Training Fellowship and Catalyst Award (to A.J.H.), ALF and the AASLD Pinnacle Award (to E.K.), NIH HL092961 (to D.J.T.), HL133320 (to D.J.T. and V.H.S.), HL126990 (to D.J.K.), a Scleroderma Foundation New Investigator Grant and an American Thoracic Society Foundation/Pulmonary Fibrosis Foundation Research Grant (to D.L.), and a Scleroderma Research Foundation Investigator-Initiated Research Grant and NIH HL108975 (to A.M.T). Author contributions: A.J.H. led the in vitro and mouse studies of lung fibrosis, with assistance from G.L., D.S., K.M.C., D.L.J., Q.T., J.M., N.C., A.M.D.E., R.D.B.J., and A.A. D.L. led the in vivo siRNA experiments. E.K. and J.L.M. performed the in vitro and mouse studies of liver fibrosis. Y.Z. and D.J.K. led the human data and tissue analysis with assistance from S.M.N. and X.L. A.C.R. analyzed the mouse tissue histology. Y.S.P., C.M.P., A.M.T., X.V., D.J.K., V.H.S., and D.J.T. supervised the project. A.J.H. and D.J.T. wrote and edited the manuscript. All the authors reviewed and provided feedback on the manuscript. Competing interests: A.J.H. and D.J.T. are coinventors of a patent application (“Methods of treating fibrotic pathologies” PCT/US2019/016178) based on some of the findings described in this manuscript. Data and materials availability: All data associated with this study are present in the paper or the Supplementary Materials.

Stay Connected to Science Translational Medicine

Navigate This Article